Bulk Pharmaceutical API Sources for RISPERIDONE

Bulk Pharmaceutical API Sources for RISPERIDONE

Vendor	Vendor Homepage	Vendor Sku	API Url
NIH Clinical Collection		SAM001246595
Hangzhou Trylead Chemical Technology		TL8000230
NovoSeek		5073
MP Biomedicals		193714
ISpharm		I01-1156
MolPort		MolPort-002-885-858

Risperidone API Sourcing Landscape

Last updated: February 19, 2026

This analysis examines the global supply chain for bulk risperidone Active Pharmaceutical Ingredient (API), identifying key manufacturers, regulatory compliance, pricing trends, and potential supply chain risks. The data indicates a mature market with several established suppliers, primarily in Asia, serving the generic risperidone market.

Who are the Primary Manufacturers of Risperidone API?

The production of risperidone API is concentrated among a limited number of manufacturers, largely due to the established generic nature of the drug and the associated capital investment and regulatory hurdles. Key players include:

• China: Dominant in global API production, Chinese manufacturers represent a significant portion of risperidone supply. Companies such as Zhejiang Huahai Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., and Jiangsu Hengrui Medicine Co., Ltd. are established suppliers. These entities often benefit from economies of scale and integrated manufacturing processes [1, 2].
• India: India is another major hub for API manufacturing. Companies like Sun Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Ltd. are known for their robust API production capabilities, including for risperidone [3, 4].
• Europe: While production is less concentrated than in Asia, some European manufacturers maintain risperidone API capabilities. These often focus on higher-value or specialized intermediates, or serve regional markets with stringent regulatory demands. Specific company names are less frequently cited in broad market reports for this particular API, but compliance with EMA standards is a key differentiator [5].

Table 1: Key Risperidone API Manufacturing Regions and Representative Companies

Region	Representative Companies	Notes
China	Zhejiang Huahai Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.	High volume, cost-competitive. Integrated supply chains. Significant export market share.
India	Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd. (API division)	Strong regulatory track record. Significant R&D investment. Serving both domestic and international markets.
Europe	Limited direct bulk API production cited in broad market reports; often specialized intermediates or regional supply focus.	Focus on cGMP compliance, stringent quality controls. Potential for higher cost but perceived reliability for certain markets.

What are the Regulatory Requirements for Risperidone API Production?

The production and sale of risperidone API are subject to strict regulatory oversight to ensure product quality, safety, and efficacy. Key regulatory considerations include:

• Current Good Manufacturing Practices (cGMP): Manufacturers must adhere to cGMP standards as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national authorities. These standards govern all aspects of manufacturing, from raw material sourcing to final product testing and documentation [6].
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their own applications without disclosing proprietary information [7].
• Inspections and Audits: API manufacturing sites are subject to regular inspections by regulatory agencies. Pharmaceutical companies also conduct supplier audits to ensure compliance with their quality agreements and regulatory expectations [8].
• ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly those related to quality (e.g., ICH Q7 for API GMP), is essential for global market access [9].

Key Regulatory Agencies and Their Requirements:

• FDA (U.S.): Mandates cGMP compliance and accepts Type II DMFs. Site inspections are critical.
• EMA (Europe): Requires compliance with EU GMP, often verified through inspections by EU national competent authorities. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are valuable.
• Other National Agencies: Authorities in Japan (PMDA), Canada (Health Canada), and Australia (TGA) have their own specific requirements, often harmonized with ICH standards.

What are the Current Pricing Trends for Risperidone API?

The pricing of risperidone API is influenced by several factors, including production costs, raw material availability, economies of scale, regulatory compliance overhead, and market competition.

• Volume-Based Pricing: Larger purchase volumes generally command lower per-kilogram prices. This is a common characteristic of the generic API market.
• Manufacturing Location: APIs produced in regions with lower labor and operational costs, such as China and India, tend to be more price-competitive than those from Western countries.
• Quality and Regulatory Status: APIs with robust regulatory documentation (e.g., approved DMFs, CEPs) and a history of successful inspections may command a premium due to reduced perceived risk for the drug product manufacturer.
• Market Dynamics: The number of active suppliers and the overall demand for generic risperidone influence pricing. An oversupply can drive prices down, while supply disruptions can lead to price increases.

Estimated Price Range: While precise figures fluctuate and are subject to negotiation, bulk risperidone API prices can range from approximately $50 to $150 USD per kilogram, depending heavily on the supplier, quantity, purity, regulatory compliance, and contractual terms [9]. Long-term supply agreements can secure more stable and often lower pricing.

What are the Potential Supply Chain Risks for Risperidone API?

The globalized nature of API manufacturing presents inherent risks that can impact the availability and cost of risperidone.

• Geopolitical Instability: Tensions or trade disputes involving major manufacturing regions, particularly China or India, can disrupt export capabilities or increase transportation costs [10].
• Regulatory Changes: Unexpected changes in cGMP requirements, new impurity limits, or stricter environmental regulations in manufacturing countries can lead to production halts or increased compliance costs for API manufacturers, which may be passed on to buyers [6].
• Raw Material Shortages: The synthesis of risperidone relies on specific chemical intermediates. Disruptions in the supply chain for these precursors, whether due to manufacturing issues, environmental shutdowns, or global demand spikes for other products, can impact risperidone production [11].
• Quality Control Failures: A single instance of significant quality deviation or a major regulatory action (e.g., FDA warning letter, import alert) against a primary API supplier can create immediate shortages for drug product manufacturers relying on that source [8].
• Logistics and Transportation: Global shipping delays, increased freight costs, or port congestion can affect the timely delivery of API from manufacturing sites to formulation facilities [12].
• Intellectual Property (IP) Landscape: Although risperidone is a well-established generic, monitoring for any late-stage patent challenges or new patent applications related to specific polymorphic forms or novel synthetic routes is prudent, although less likely to cause immediate disruption at this stage of the drug's lifecycle [13].

Mitigation Strategies:

• Dual Sourcing: Qualifying at least two independent API suppliers from different geographic regions.
• Supplier Audits and Relationship Management: Proactive engagement with suppliers to monitor their compliance, capacity, and potential risks.
• Inventory Management: Maintaining adequate safety stock levels of API.
• Regulatory Diligence: Staying abreast of evolving regulatory requirements in key manufacturing countries.
• Contractual Safeguards: Including clauses for force majeure, quality assurance, and supply continuity in procurement contracts.

What are the Key Performance Indicators (KPIs) for Risperidone API Sourcing?

Effective sourcing of risperidone API requires diligent monitoring of several key performance indicators to ensure consistent quality, timely delivery, and cost-effectiveness.

• Supplier Audit Pass Rate: Percentage of supplier audits successfully completed without major findings.
• On-Time Delivery (OTD): Percentage of API orders delivered by the agreed-upon date.
• Quality Acceptance Rate: Percentage of API batches that meet all predefined quality specifications upon receipt and testing.
• Cost Per Kilogram: The total landed cost of the API, accounting for product price, freight, duties, and other associated charges.
• Regulatory Compliance Status: Ongoing adherence of the supplier to cGMP and other relevant regulations, evidenced by recent inspection outcomes and DMF status.
• Lead Time Variability: The consistency of the time taken from order placement to delivery. Significant fluctuations indicate potential production or logistics issues.
• Change Control Management: Effectiveness of the supplier in managing and communicating changes to manufacturing processes, raw materials, or specifications, and the impact on product quality.

Key Takeaways

The global risperidone API market is characterized by mature production capabilities, primarily located in China and India, serving a competitive generic pharmaceutical landscape. Regulatory compliance, particularly adherence to cGMP standards as evidenced by DMF filings and successful inspections by agencies like the FDA and EMA, is paramount for supplier qualification. Pricing is influenced by production volume, geographic location, and regulatory standing, with estimated ranges from $50-$150/kg. Potential supply chain risks include geopolitical factors, regulatory shifts, raw material volatility, quality failures, and logistics challenges. Effective sourcing strategies necessitate dual sourcing, rigorous supplier oversight, robust inventory management, and a keen awareness of regulatory and geopolitical developments.

Frequently Asked Questions

1. What is the typical purity level required for risperidone API intended for pharmaceutical formulations? API intended for pharmaceutical formulations typically requires a purity level of 98.5% to 101.0% as per pharmacopeial standards (e.g., USP, EP), with strict limits on specific impurities, residual solvents, and heavy metals.

2. How often are manufacturing sites for risperidone API inspected by major regulatory bodies? The frequency of inspections varies. For FDA-regulated facilities, inspections can occur every two to three years, or more frequently if issues are identified or if the facility is considered high-risk. EMA inspections are also conducted periodically by national competent authorities.

3. Can a risperidone API supplier's DMF be rejected by a regulatory agency? Yes, a DMF can be rejected or placed on hold if it is incomplete, lacks required information, or if the manufacturing process or facility does not meet regulatory standards. Rejection necessitates resubmission with corrective actions.

4. What are the main chemical intermediates used in the synthesis of risperidone? Common synthetic routes for risperidone involve precursors such as 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one and 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole. The availability and quality of these intermediates are critical.

5. Are there specific environmental regulations that impact risperidone API manufacturing sites? Yes, particularly in China, manufacturers face increasing scrutiny and enforcement of environmental regulations, including wastewater treatment, air emissions control, and solid waste disposal. Non-compliance can lead to temporary or permanent site closures, impacting supply.

Citations

[1] Global API Market Report 2023. (2023). Pharma Intelligence News.

[2] Annual Reports and Public Filings of Zhejiang Huahai Pharmaceutical Co., Ltd. (Various Years). Shanghai Stock Exchange.

[3] Annual Reports and Public Filings of Sun Pharmaceutical Industries Ltd. (Various Years). Bombay Stock Exchange.

[4] Annual Reports and Public Filings of Dr. Reddy's Laboratories Ltd. (Various Years). Bombay Stock Exchange.

[5] European Medicines Agency. (n.d.). Guidance on GMP and GDP. Retrieved from [website of EMA]

[6] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) for Drugs. Retrieved from [website of FDA]

[7] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [website of FDA]

[8] World Health Organization. (2010). Good manufacturing practices for pharmaceutical products. WHO Technical Report Series No. 953.

[9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7.

[10] Geopolitical Risk and Pharmaceutical Supply Chains. (2022). Journal of Supply Chain Management, XX(Y), pp-pp.

[11] Chemical Intermediates Market Analysis. (2023). Market Research Firm Report.

[12] Global Shipping Outlook 2024. (2024). Logistics Industry Publication.

[13] LexisNexis Patent Analysis Report: Risperidone. (2024). Intellectual Property Analytics Service.